Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.11 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (neutrophil progenitors) | 0.10 |
| chemistry Open Targets | compounds already reach it: rebimastat, azd-1236, andecaliximab +2 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 108 Parkinson's papers of 39,628 | 0.38 |
| pathways Reactome | 10 pathways; mostly protein handling | 0.90 |
No case: the score is under the bar. Receipt 2416
Sealed predictions
- MMP9 in dopamine neurons, braak-0.41 (p 0.273) → +0.42 (p 0.258)receipt 2424
Swarm cases
receipt 2424: MMP9 in dopamine neurons, braak
- power
- full sample +0.04 (p 0.888, n 18), 95% CI -0.44 to +0.49. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.05 (p 0.834, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.02 (p 0.949, n 18). could be the mix.
- skeptic
- leave-one-out range -0.11 to +0.14, sign flips 3; without severely affected donors +0.04 (p 0.888, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MMP9 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts